MARATTO

preprint · Research Square (Research Square)

Unique Sustain Anticancer Modified Chitosan Nanoparticle: Fabrication and Characterization

2024Open accessAin Shams University

Abstract

<title>Abstract</title> Chitosan (CS) is a biopolymer offers a wide range in biomedical applications due to its biocompatibility, biodegradability, low toxicity and antimicrobial activity. Syringaldehyde (1) is naturally organic compound characterized by its uses in multiple fields such as pharmaceuticals, food, cosmetics, textiles and biological applications. Herein, development of chitosan physicochemical and anticancer properties via Schiff base formation from the reaction of chitosan with sustainable eco-friendly syringaldehyde yielded (CS-1) derivative. Moreover, in presence of polyethylene glycol diglycidyl ether (PEGDGE) or sodium tripolyphosphate (TPP) as crosslinkers gave chitosan derivatives (CS-2) and (CS-3NPs) respectively. The chemical structures of new chitosan derivatives are confirmed using different tools. (CS-3NPs) nanoparticle showed improvement in crystallinity, and (CS-2) derivative revealed the highest thermal stability compared to virgin chitosan. The cytotoxicity activity of chitosan and its derivatives is evaluated against HeLa (human cervical carcinoma) and HEp-2 (Human Larynx carcinoma) cell lines. The highest cytotoxicity activity is exhibited by (CS-3NPs) compared to virgin chitosan against HeLa cell growth inhibition and apoptosis of 90.38±1.46% and 30.3% respectively and <italic>IC</italic><sub><italic>50</italic></sub> of 108.01±3.94 µg/ml. From the above results, it can be concluded that chitosan nanoparticle (CS-3NPs) might be good therapeutic value as a potential antitumor agent against HeLa cancer cell line.

Research topics

  • Nanoparticle-Based Drug Delivery
  • Advanced Drug Delivery Systems
  • Graphene and Nanomaterials Applications

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21203/rs.3.rs-4213251/v1

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.